PBYI: pumabiotechnology.com Company Value to Net Income

Puma Biotechnology, Inc. - graphic logo of issuer PBYI

Declining sales volumes of its primary drug are limiting the natural growth of Puma Biotechnology (PBYI), necessitating strict oversight of the R&D budget. The price action on GURU.Markets with a value of 18.40 links these risks to the performance of management, which has successfully commercialized Nerlynx but is now seeking diversification paths. Puma Biotechnology (PBYI) specializes in the therapy of HER2-positive tumors, relying on international licenses and the expansion of medical indications for its flagship product.

P/E Multiple: Puma Biotechnology Inc (PBYI) for 07/04/2022 - 11/10/2026

Comprehensive metric breakdowns and analytics for Puma Bio (PBYI)

- share price and consensus valuation forecast:
Price Puma Biotechnology Inc|PBYI - Consensus Target
- market capitalization information:
Market Value Puma Biotechnology, Inc.|PBYI - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share Puma Biotechnology|PBYI - Book Capitalization|Market Capitalization to Book Value Ratio pumabiotechnology.com|PBYI - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Ratio Puma Biotechnology|PBYI - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Puma Biotechnology Inc|PBYI - Company Aggregate Debts|Debts to Book Value Puma Biotechnology, Inc.|PBYI - Company Long-Term Debt|Company Short-Term Loans and Borrowings Puma Biotechnology|Critical Liquidity Ratio pumabiotechnology.com
- company profitability and valuation multiples indicators:
PBYI - Net Income|Projected Future Earnings Puma Biotechnology|PBYI - Price to Earnings Ratio|Projected Price to Earnings Puma Biotechnology Inc|PBYI - PEG Multiple|EV/EBITDA Multiple Puma Biotechnology, Inc.|PBYI - Operating profit before deduction of amortization|Earnings per share for the trailing year Puma Biotechnology|PBYI - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months pumabiotechnology.com|PBYI - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Puma Biotechnology
Summary company analysis:PBYI (pumabiotechnology.com)
Product sample of Puma Biotechnology

Investors are evaluating Puma Biotechnology (PBYI) through the lens of Nerlynx's dominance in HER2-positive cancer therapy. The P/E ratio measures the cost per unit of profit, reflecting market expectations for the monetization rates of this biopharmaceutical ecosystem. Analyzing the company's rolling P/E with a value of 18.40 allows for the removal of volatility to reveal the real valuation dynamics of the business. The long-term consensus is based on the issuer's ability to maintain high patient switching barriers.

Analysis of competing companies

OLMA (olema.com) - Market Price to Net Income Ratio|Price to Earnings Ratio GLSI (Greenwich LifeSciences, Inc.)|ZNTL (Zentalis Pharmaceuticals, Inc.) - Company Value to Net Income|P/E Multiple MGNX (MacroGenics Corp)|PSTV - Price to Earnings Ratio|Processa Pharma - P/E Multiple|EGRX - P/E Multiple